Monocyte and interferon based therapy for the treatment of ovarian cancer.
Monocyte and interferon based therapy for the treatment of ovarian cancer.
复制标题
DOI：
10.1016/j.cytogfr.2016.02.006
复制
发表时间：
2016-06
影响因子：
13
通讯作者：
Zoon KC
中科院分区：
文献类型：
--
作者：
Green DS;Nunes AT;Annunziata CM;Zoon KC
细胞因子和先天免疫系统细胞已被证明是恶性细胞消除、平衡和逃逸的关键调节因子。尽管有体外和体内的证据，先天免疫系统的成分在卵巢癌的治疗中显示出有限的功效。腹腔免疫疗法是一个很有前途的领域，但在卵巢癌中尚未得到充分的探索。使用干扰素α (IFN-α)和干扰素γ (IFN-γ)的细胞因子免疫疗法主要用于腹腔内治疗卵巢癌，并取得了令人鼓舞的结果。早期研究还表明，注入腹膜的自体单核细胞具有抗肿瘤特性。在治疗癌症方面，联合疗法已被证明比单一疗法更有效。基于这些观察结果，细胞治疗与细胞因子治疗的结合可能为化疗耐药实体癌的治疗提供一种独特的策略。
Cytokines and cells of the innate immune system have been shown to be critical regulators in the elimination, equilibrium and escape of malignant cells. Despite in vitro and in vivo evidence, components of the innate immune system have shown limited efficacy in the treatment of ovarian cancer. Intraperitoneal immunotherapies are a promising field that has not yet been fully explored in ovarian cancer. Cytokine immunotherapy using interferon alpha (IFN-α) and interferon gamma (IFN-γ) has predominantly been used intraperitoneally in ovarian cancer, with promising results. Early studies also showed that autologous monocytes infused into the peritoneum have anti-tumor properties. Combination therapies have been shown to be more effective in treating cancer than monotherapies. Based on these observations the combination of cell therapy with cytokine therapy may provide a unique strategy for the treatment of chemotherapy resistant solid cancers.